About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
PMID: 34286374 Journal: EUROPEAN JOURNAL OF PEDIATRICS Year: 2022 Reference: Eur J Pediatr. 2022 Jan;181(1):287-294. doi: 10.1007/s00431-021-04175-z. Epub 2021 Jul 20. Impact factor: 3.183 Publication type: Paper in international publication Authors: Fernandez-Alvarez, Paula, Codina-Sola, Marta, Balcells, Joan, Izquierdo-Blasco, Jaume, Gran, Ferran, Garrido, Marta, Dolader, Paola, Fidalgo, Andrea, Navarro, Alexandra, Sabate-Rotes, Anna et al. DOI: 10.1007/s00431-021-04175-z
PMID: 35024431 Journal: International journal of cardiology. Heart & vasculature Year: 2022 Reference: Int J Cardiol Heart Vasc. 2021 Dec 29;38:100941. doi: 10.1016/j.ijcha.2021.100941. eCollection 2022 Feb. Impact factor: 0 Publication type: Paper in international publication Authors: Ibanez Criado, Jose L, Palazuelos, Jorge, Albarran Rincon, Ramon, Mohandes, Mohsen, Rodriguez Entem, Felipe-Jose, Marti, Gerard, Valero, Ernesto, Gutierrez, Hipolito, Amat-Santos, Ignacio J, Nombela-Franco, Luis et al. DOI: 10.1016/j.ijcha.2021.100941
PMID: 34999818 Journal: European Heart Journal-Cardiovascular Imaging Year: 2022 Reference: Eur Heart J Cardiovasc Imaging. 2022 Jan 6. pii: 6498863. doi: 10.1093/ehjci/jeab279. Impact factor: 6.875 Publication type: Paper in international publication Authors: Escobar, Manuel, Roque, Albert, Pizzi, Maria N, Fernandez-Hidalgo, Nuria, Romero-Farina, Guillermo, Burcet, Gemma, Reyes-Juarez, Jose Luis, Espinet, Carina, Castell-Conesa, Joan, Cuellar-Calabria, Hug et al. DOI: 10.1093/ehjci/jeab279
PMID: 34115857 Journal: EUROPACE Year: 2022 Reference: Europace. 2022 Jan 4;24(1):4-11. doi: 10.1093/europace/euab131. Impact factor: 5.214 Publication type: Paper in international publication Authors: Rivera-Caravaca, Jose Miguel, Badimon, Lina, Ferreira-Gonzalez, Ignacio, Gomez-Doblas, Juan Jose, Roca-Luque, Ivo, Lekuona, Inaki, Jimenez-Candil, Javier, Rodriguez-Padial, Luis, Gonzalez-Juanatey, Carlos, Calvo-Jambrina, Roman et al. DOI: 10.1093/europace/euab131
PMID: 33733675 Journal: CLINICAL INFECTIOUS DISEASES Year: 2021 Reference: Clin Infect Dis. 2021 Dec 6;73(11):e3750-e3758. doi: 10.1093/cid/ciaa1941. Impact factor: 9.079 Publication type: Paper in international publication Authors: Regueiro, Ander, Munoz-Garcia, Antonio, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio, Kapadia, Samir et al. DOI: 10.1093/cid/ciaa1941
PMID: 33716106 Journal: FREE RADICAL BIOLOGY AND MEDICINE Year: 2021 Reference: Free Radic Biol Med. 2021 May 1;167:109-124. doi: 10.1016/j.freeradbiomed.2021.02.043. Epub 2021 Mar 11. Impact factor: 7.376 Publication type: Paper in international publication Authors: Bou-Teen, Diana, Kaludercic, Nina, Weissman, David, Turan, Belma, Maack, Christoph, Di Lisa, Fabio, Ruiz-Meana, Marisol et al. DOI: 10.1016/j.freeradbiomed.2021.02.043
PMID: 33712406 Journal: ANALES DE PEDIATRIA Year: 2021 Reference: An Pediatr (Engl Ed). 2021 Mar 9. pii: S1695-4033(20)30498-7. doi: 10.1016/j.anpedi.2020.11.012. Impact factor: 1.5 Publication type: Letter whit IF Authors: Brunet-Garcia, Laia, Roses-Noguer, Ferran, Betrian, Pedro, Balcells, Joan, Gran, Ferran et al. DOI: 10.1016/j.anpedi.2020.11.012
PMID: 33712348 Journal: REVISTA ESPANOLA DE CARDIOLOGIA Year: 2021 Reference: Rev Esp Cardiol (Engl Ed). 2021 May;74(5):438-448. doi: 10.1016/j.rec.2020.11.020. Epub 2021 Mar 10. Impact factor: 4.753 Publication type: Paper in national publication Authors: Garcia Sanz, Ramon, Martin Garcia, Ana, Mitroi, Cristina, Mazon Ramos, Pilar, Reinoso-Barbero, Luis, Rodriguez, Isabel, Serrano Antolin, Jose Maria, Toral, Belen, Torres Royo, Laura, Velasco Del Castillo, Sonia et al. DOI: 10.1016/j.rec.2020.11.020
The consensus document is the result of multidisciplinary work that takes into account the risks associated with all stages of women's lives and the differences compared to men.
The study, which involved Vall d'Hebron, developed an action plan to efficiently allocate resources to patients most at risk of suffering this complication.
In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.
